Joint Clinical Trials Office
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 30, 2026
MASTER SCREENING STUDY TO DETERMINE POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH ALZHEIMER’S DISEASE AS ASSESSED BY THEIR BIOMARKER STATUS AND COGNITION
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 30, 2026
EoE-201, A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects with Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20mg to Evaluate the Safety and Efficacy of Vonoprazan 20mg Compared to Placebo
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 21, 2026
A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 16, 2026
The underappreciated role of atherosclerotic cardiovascular disease in primary biliary cholangitis
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 16, 2026
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged AML
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
A Phase III, Multisite, Double-Blinded Randomized Trial of BNT327 In Combination with Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab In Combination with Chemotherapy In Participants with First-Line Extensive-Stage Small-Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
FMT and Other Gut Microbial Therapies National Registry: Acute Severe and Fulminant C. Difficile Infection
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
GS-US-567-6968: Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
Prospective randomized study of the Kono-S anastomosis versus the side-to-side functional end anastomosis in the prevention of post-operative recurrence of Crohn’s disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 30, 2026